経鼻ワクチン市場- 世界の産業規模、シェア、動向、市場機会、予測、ワクチンタイプ別、用途別、地域別、競合別、2020～2030年

経鼻ワクチンの世界市場規模は、2024年には4億2,520万米ドルとなり、2030年までのCAGRは6.05%で、予測期間中に目覚ましい成長を遂げると予測されています。

世界のヘルスケア事情は絶えず進化しており、最近の重要な動向として経鼻ワクチンの登場が挙げられます。経鼻ワクチンは、様々な感染症から身を守る斬新で効果的な方法を提供し、従来の注射ベースのワクチンに代わる非侵襲的な選択肢を提供します。経鼻ワクチンの世界市場は、ワクチン技術の進歩やその利点に対する認知度の向上により、勢いを増しています。経鼻ワクチンの世界市場は近年、いくつかの重要な要因によって大きな成長を遂げています。痛みの少ない便利なワクチン接種方法に対する需要の高まり、予防ヘルスケアへの注目の高まり、革新的な経鼻ワクチン製剤の開発などです。経鼻ワクチンは、特に小児や注射針を怖がる人々にとって魅力的であり、予防接種のための好ましい選択肢となっています。市場では、経鼻投与されるワクチンの種類が拡大しています。当初、経鼻ワクチンは主にインフルエンザワクチンと関連していましたが、現在ではCOVID-19、麻疹、おたふくかぜ、風疹など、より幅広い疾患をカバーしています。このような市場の多様化が市場を大きく押し上げています。製薬会社や研究機関は、より効果的で強力な経鼻ワクチン製剤を開発するため、積極的に研究開発に投資しています。これには、経鼻ワクチンの安定性や送達メカニズムの強化も含まれます。

政府や国際機関は、ワクチン接種率向上における経鼻ワクチンの可能性をますます認識しつつあります。このため、特に低所得国や中所得国において、経鼻ワクチンを使用した研究やワクチン接種キャンペーンへの投資が拡大しています。経鼻ワクチンの普及には、国民の意識向上キャンペーンや教育活動が重要な役割を果たしています。これらのキャンペーンでは、痛みの軽減、投与の容易さ、免疫力の発達の早まりといった経鼻ワクチンの利点が強調されています。

主な市場促進要因

感染症および呼吸器系疾患の罹患率の増加

感染症や呼吸器系疾患の罹患率の増加は、経鼻ワクチンの世界市場拡大を促進する主要因です。インフルエンザ、COVID-19、結核、呼吸器合胞体ウイルス（RSV）などの疾病の世界的な負担が増加の一途をたどるなか、効果的で利用しやすく、非侵襲的なワクチン接種ソリューションに対する需要が高まっています。季節性インフルエンザと結核の蔓延により、世界のヘルスケア部門は大きな課題に直面しています。季節性インフルエンザは毎年、世界中で約10億人が罹患し、300～500万人が重症化します。この病気は、年間29～65万人の呼吸器に関連した死亡の原因となると推定され、ヘルスケアシステムと経済生産性に大きな負担を与えています。

同様に、結核も依然として世界保健上の重要な課題です。2023年だけでも、世界中で推定1,080万人が結核に罹患し、男性600万人、女性360万人、子ども130万人が罹患しています。この病気はすべての国と年齢層に影響を与え続けており、公衆衛生上の負担が拡大しています。結核は治すことも予防することも可能であるにもかかわらず、早期発見、治療へのアクセス、ヘルスケアのインフラに格差があるため、依然として蔓延しています。経鼻ワクチンは、特に空気中に浮遊する病原体に対する標的免疫反応を提供するため、従来の注射ワクチンに代わる非常に魅力的なワクチンです。呼吸器疾患は、世界的に罹患率および死亡率の主要な原因の一つです。インフルエンザだけでも毎年数百万人が罹患し、入院、経済的負担、生産性の低下を招いています。同様に、COVID-19のような新興感染症は、スケーラブルで容易に展開できるワクチン接種戦略の必要性を強めています。2020年には、慢性閉塞性肺疾患（COPD）が世界人口の推定10.6％に影響を及ぼし、男女合わせて4億8,000万人が罹患することになります。この慢性呼吸器疾患は、公衆衛生上の大きな懸念事項として拡大し続けており、2050年までに23.3％増加すると予測されています。その頃には、COPDの総患者数は5億9,200万人に達し、世界のリスク人口の9.5％を占めると予想されています。経鼻ワクチンは、空気感染するウイルスやバクテリアの自然な感染経路を模倣しているため、呼吸器疾患の予防に特に効果的です。感染率の高い国では予防接種戦略への投資が増加しており、鼻腔ワクチン技術の採用が加速しています。

主な市場課題

規制上のハードル

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 経鼻ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ワクチンタイプ別（生弱毒ワクチン、不活化ワクチン、サブユニットワクチン、組み換えワクチン、結合ワクチン、その他）
  • 用途別（インフルエンザ、 COVID-19、その他（コレラ、腸チフスなど））
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の経鼻ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の経鼻ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の経鼻ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の経鼻ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの経鼻ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の経鼻ワクチン市場：SWOT分析

第14章 競合情勢

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Nasal Vaccines Market was valued at USD 425.20 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.05% through 2030. The global healthcare landscape is continually evolving, and one significant development in recent years is the emergence of nasal vaccines. Nasal vaccines offer a novel and effective way to protect against various infectious diseases, providing a non-invasive alternative to traditional injection-based vaccines. The global nasal vaccines market has been gaining momentum, with advancements in vaccine technology and increasing awareness of their benefits. The global nasal vaccines market has witnessed substantial growth in recent years, driven by several key factors. These include a rising demand for painless and convenient vaccination methods, increased focus on preventive healthcare, and the development of innovative nasal vaccine formulations. Nasal vaccines are particularly appealing for children and individuals who fear needles, making them a preferred choice for immunization. The market has seen the expansion of the types of vaccines delivered nasally. Initially, nasal vaccines were primarily associated with influenza vaccines, but now they cover a wider range of diseases, including COVID-19, measles, mumps, rubella, and more. This diversification has significantly boosted the market. Pharmaceutical companies and research institutions are actively investing in R&D to develop more effective and potent nasal vaccine formulations. This includes enhancing the stability and delivery mechanisms of nasal vaccines.

Governments and international organizations are increasingly recognizing the potential of nasal vaccines in improving vaccination coverage rates. This has led to greater investments in research and vaccination campaigns using nasal vaccines, particularly in low-income and middle-income countries. Public awareness campaigns and educational efforts are playing a vital role in increasing the acceptance of nasal vaccines. These campaigns highlight the advantages of nasal vaccines, such as reduced pain, easier administration, and quicker immunity development.

Ky Market Drivers

Growing Prevalence of Infectious and Respiratory Diseases

The rising incidence of infectious and respiratory diseases is a key driver fueling the expansion of the global nasal vaccines market. As the global burden of diseases such as influenza, COVID-19, tuberculosis (TB), and respiratory syncytial virus (RSV) continues to escalate, there is an increasing demand for effective, accessible, and non-invasive vaccination solutions. The global healthcare sector faces significant challenges due to the widespread prevalence of seasonal influenza and tuberculosis (TB). Each year, seasonal influenza affects approximately one billion people worldwide, with 3 to 5 million cases progressing to severe illness. The disease is responsible for an estimated 290,000 to 650,000 respiratory-related deaths annually, creating substantial strain on healthcare systems and economic productivity.

Similarly, tuberculosis (TB) remains a critical global health challenge. In 2023 alone, an estimated 10.8 million people contracted TB worldwide, affecting 6.0 million men, 3.6 million women, and 1.3 million children. The disease continues to impact all countries and age groups, reinforcing its widespread public health burden. Despite being both curable and preventable, TB persists due to gaps in early detection, treatment access, and healthcare infrastructure. Nasal vaccines provide a targeted immune response, particularly against airborne pathogens, making them a highly attractive alternative to traditional injectable vaccines. Respiratory diseases are among the leading causes of morbidity and mortality worldwide. Influenza alone affects millions annually, leading to hospitalizations, economic strain, and loss of productivity. Similarly, emerging infectious diseases like COVID-19 have reinforced the need for scalable and easily deployable vaccination strategies. In 2020, chronic obstructive pulmonary disease (COPD) affected an estimated 10.6% of the global population, translating to 480 million cases across both men and women. This chronic respiratory condition continues to expand as a major public health concern, with projections indicating a 23.3% increase in cases by 2050. By that time, the total number of COPD cases is expected to reach 592 million, representing 9.5% of the global at-risk population. Nasal vaccines are particularly effective in preventing respiratory diseases because they mimic the natural infection route of airborne viruses and bacteria. Countries with high infection rates are increasingly investing in preventive immunization strategies, thereby accelerating the adoption of nasal vaccine technologies.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the nasal vaccines market is navigating the complex regulatory landscape. The approval process for nasal vaccines can be more challenging compared to traditional injectable vaccines. Regulators need to ensure the safety and efficacy of these vaccines, which can lead to longer development timelines and higher costs. To address this challenge, collaboration between vaccine developers and regulatory agencies is essential to streamline the approval process and establish clear guidelines for nasal vaccine development.

Key Market Trends

Technological Advancements

The global healthcare landscape is constantly evolving, with technological advancements at the forefront of innovation. One significant development is the growing interest in nasal vaccines, a novel approach to immunization that offers numerous advantages over traditional injection-based vaccines. These advancements have ignited a surge in the Global Nasal Vaccines Market, shaping the future of preventive medicine and public health.

Advancements in vaccine formulation have played a pivotal role in the growth of nasal vaccines. Researchers are developing new formulations that enhance vaccine stability, improve antigen delivery, and minimize side effects, thereby increasing their efficacy and safety. Adjuvants are substances added to vaccines to boost the body's immune response. Recent developments in adjuvant technology have led to the creation of nasal vaccines that can trigger stronger and more durable immune responses, improving their overall effectiveness.

Key Market Players

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

Report Scope:

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit
• Recombinant and Conjugate Vaccines
• Others

Nasal Vaccines Market, By Application:

• Influenza
• COVID-19
• Others

Nasal Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Nasal Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant and Conjugate Vaccines, Others)
  • 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nasal Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nasal Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nasal Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nasal Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nasal Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Nasal Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Nasal Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Nasal Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nasal Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Nasal Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Nasal Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nasal Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nasal Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nasal Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nasal Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Application

9. South America Nasal Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nasal Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Nasal Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Nasal Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Nasal Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nasal Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Nasal Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Nasal Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Nasal Vaccines Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Vaxart, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. FluGen Inc.
• 14.3. Altimmune, Inc.
• 14.4. Sinovac Biotech Ltd.
• 14.5. Sanofi Pasteur SA
• 14.6. Pfizer Inc.
• 14.7. GlaxoSmithKline plc
• 14.8. Johnson & Johnson
• 14.9. Ennaid Therapeutics, LLC

15. Strategic Recommendations

16. About Us & Disclaimer